Literature DB >> 14506715

Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid.

Masahide Yazaki1, Juris J Liepnieks, John C Kincaid, Merrill D Benson.   

Abstract

To elucidate the contribution of wild-type transthyretin (TTR) to amyloid polyneuropathy in TTR amyloidosis, we biochemically investigated amyloid fibrils isolated from sciatic nerve of an autopsied patient with TTR Ala25Ser variant and compared the amount of wild-type and variant TTR in the nerve to that in the heart. Amyloid subunit protein from isolated fibrils was solubilized in 6M guanidine HCl and purified by gel filtration chromatography. The relative amounts of variant and wild-type TTR in the purified protein were estimated from the recovered amounts of tryptic peptides with Ser25 or Ala25. Approximately 60% variant and 40% wild-type TTR were found in both the nerve and heart amyloid deposits. Our results indicate that wild-type TTR co-deposits in the peripheral nerves with variant TTR as amyloid fibril, and therefore that progression of amyloid deposition in the peripheral nerves from wild-type TTR may occur after liver transplantation, as has been seen in the heart.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506715     DOI: 10.1002/mus.10452

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

1.  CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE.

Authors:  Jorge Ghiso; Yasushi Tomidokoro; Tamas Revesz; Blas Frangione; Agueda Rostagno
Journal:  Hirosaki Igaku       Date:  2010-07-08

2.  Mass spectrometry analysis reveals non-mutated apolipoprotein A1 lumbosacral radiculoplexus amyloidoma.

Authors:  Adam J Loavenbruck; Vinay Chaudhry; Steven R Zeldenrust; Robert J Spinner; Jason D Theis; Christopher J Klein
Journal:  Muscle Nerve       Date:  2012-11       Impact factor: 3.217

3.  Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AbetaD23N in parenchymal and cerebrovascular amyloid deposits.

Authors:  Yasushi Tomidokoro; Agueda Rostagno; Thomas A Neubert; Yun Lu; G William Rebeck; Blas Frangione; Steven M Greenberg; Jorge Ghiso
Journal:  Am J Pathol       Date:  2010-03-12       Impact factor: 4.307

4.  Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study.

Authors:  David Adams; Teresa Coelho; Laura Obici; Giampaolo Merlini; Zoia Mincheva; Narupat Suanprasert; Brian R Bettencourt; Jared A Gollob; Pritesh J Gandhi; William J Litchy; Peter J Dyck
Journal:  Neurology       Date:  2015-07-24       Impact factor: 9.910

5.  Progression of transthyretin amyloid neuropathy after liver transplantation.

Authors:  Juris J Liepnieks; Lucy Q Zhang; Merrill D Benson
Journal:  Neurology       Date:  2010-07-27       Impact factor: 9.910

Review 6.  Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies.

Authors:  Tamas Revesz; Janice L Holton; Tammaryn Lashley; Gordon Plant; Blas Frangione; Agueda Rostagno; Jorge Ghiso
Journal:  Acta Neuropathol       Date:  2009-02-19       Impact factor: 17.088

Review 7.  Cerebral amyloidosis: amyloid subunits, mutants and phenotypes.

Authors:  A Rostagno; J L Holton; T Lashley; T Revesz; Jorge Ghiso
Journal:  Cell Mol Life Sci       Date:  2009-11-07       Impact factor: 9.261

Review 8.  Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis.

Authors:  Veena Mathew; Annabel K Wang
Journal:  Drug Des Devel Ther       Date:  2019-05-06       Impact factor: 4.162

9.  Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.

Authors:  Ole B Suhr; Teresa Coelho; Juan Buades; Jean Pouget; Isabel Conceicao; John Berk; Hartmut Schmidt; Márcia Waddington-Cruz; Josep M Campistol; Brian R Bettencourt; Akshay Vaishnaw; Jared Gollob; David Adams
Journal:  Orphanet J Rare Dis       Date:  2015-09-04       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.